Register for free to
view the full innovation profile.
Glucosamine analog showed benefits on maintaining/improving bone health in multiple models of arthritis and osteoporosis. Effects similar or better than existing Rx products
About
We have granted US and Canadian IP on the use of N-butyryl glucosamine (NBG) treat osteoarthritis and osteoporosis. In rodent models of arthritis and osteoporosis NBG provides antiinflammatory and antierosive effects by preserving bone mineral density and content, joint integrity, and bone architecture in involved joints. Furthermore NBG significantly benefited bone mechanical properties (increased energy to fail in femora, ultimate displacement and ultimate strain). Indeed the benefits in these models of NBG compare favaourably to those of existing market leading treatments Forteo (teriparatide) and Actonel (risedronate) in the same model and indeed exceed their benefits in some cases.
Key Benefits
1) NBG is an oral treatment that, to date appears very safe in studies we have done (no toxicity in cell cultures, no mutagenicity in Ames test, no apparent adverse events in rats up to 12,000 mg/kg). 2) Comparative preclinical models to existing drugs indicate similar if not better efficacy (rodents) and canine osteoarthritis trial data showed similar benefits to carprofen (COX-2 inhibitor) on efficacy and quality of life.
Applications
-maintaining human bone health -treating both/either human osteoarthritis and osteoporosis